Inactive Instrument
Pluristem Therapeutics Share Price Nasdaq
Stocks
Biotechnology & Medical Research
| Market Cap | 11.6M 10.36M 9.63M 8.76M 16.47M 1.1B 16.77M 116M 45.24M 573M 43.55M 42.62M 1.83B | P/E 2025 |
-1.39x | P/E 2026 | -0.85x |
|---|---|---|---|---|---|
| Enterprise Value | 38.71M 34.56M 32.12M 29.21M 54.96M 3.67B 55.95M 386M 151M 1.91B 145M 142M 6.12B | EV / Sales 2025 |
39,078,124x | EV / Sales 2026 | 48,916,935x |
| Free-Float |
57.48% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | +3.38% |
| Manager | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 54 | 28/03/2017 |
Liat Zalts
DFI | Director of Finance/CFO | 42 | 30/11/2022 |
Ori Shalem
COO | Chief Operating Officer | - | 31/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
BRD | Director/Board Member | 54 | 31/01/2015 |
| Director/Board Member | 56 | 05/01/2021 | |
| Director/Board Member | 64 | 31/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.38% | -1.33% | - | - | 11.6M | ||
| +0.21% | -4.63% | +55.34% | +71.32% | 68.98B | ||
| +0.08% | +4.28% | +6.81% | +61.62% | 53.15B | ||
| -0.48% | +5.35% | +9.96% | +41.47% | 50.83B | ||
| +3.45% | +4.70% | +33.44% | +35.96% | 44.61B | ||
| -2.20% | +0.61% | +281.88% | +532.76% | 40.57B | ||
| +6.43% | +6.84% | +18.32% | +109.23% | 42.53B | ||
| +1.28% | +1.39% | +11.69% | +45.10% | 30.95B | ||
| -0.90% | -10.49% | +31.48% | -1.63% | 25.44B | ||
| +1.74% | -2.02% | -13.55% | -12.92% | 22.66B | ||
| Average | +1.30% | +1.56% | +48.37% | +98.10% | 42.19B | |
| Weighted average by Cap. | +1.03% | +2.33% | +50.69% | +103.30% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 1.34 1.19 1.11 1.01 1.9 126.54 1.93 13.31 5.21 66.02 5.01 4.91 211.27 | 1.02 0.91 0.84 0.77 1.44 96.23 1.47 10.12 3.96 50.21 3.81 3.73 160.66 |
| Net income | -22.58M -20.16M -18.73M -17.04M -32.06M -2.14B -32.64M -225M -88.05M -1.12B -84.75M -82.95M -3.57B | -23.82M -21.26M -19.76M -17.98M -33.82M -2.26B -34.43M -237M -92.88M -1.18B -89.39M -87.5M -3.77B |
| Net Debt | 13.44M 11.99M 11.15M 10.14M 19.08M 1.27B 19.42M 134M 52.39M 664M 50.43M 49.36M 2.12B | 27.11M 24.2M 22.49M 20.46M 38.49M 2.57B 39.18M 270M 106M 1.34B 102M 99.58M 4.29B |
Employees
-
















